238 results about "Oxetane" patented technology

The invention provides light-cured epoxy ink and a preparation method and application thereof, the light-cured epoxy ink comprises an alicyclic epoxy monomer, an oxetane monomer, a diluent, a photoinitiator, an adhesion promoter and an assistant, the alicyclic epoxy monomer is an alicyclic epoxy monomer containing more than two polycyclic rings in a molecule; and the adhesion promoter is glycidyl ether epoxy micromolecules containing hydroxyl groups. According to the epoxy ink composition disclosed by the invention, the rigid group alicyclic ring and the adhesion promoter with hydroxyl are introduced, so that the epoxy ink composition has high adhesion and film surface hardness at the same time. The light-cured printing ink provided by the invention has low viscosity and high light transmittance. The liquid crystal composition is suitable for the field of display panels such as OLEDs, Micro-LEDs and the like, and the ink-jet printing technology is met.

Provided are: a curable composition that has, at high standards, curability, mechanical strength, and low viscosity; a cured product of the same; an adhesive; and a sealant. The curable composition contains an epoxy-oxetane compound represented by chemical formula (I). In the formula, the Rs are the same or different, and each represents a hydrogen atom or a C1-3 alkyl group.

The invention provides a halohydrin dehalogenase mutant and an application of the halohydrin dehalogenase mutant in synthesis of a chiral gamma-amino alcohol compound. Halogenated alcohol dehalogenase mutants enabling 2-substituted oxetane to be subjected to ring opening are obtained through the technologies of gene mining, directed evolution and the like, and the enzymes can directly perform ring opening on a substrate 2-aryl oxetane under the action of a nucleophilic reagent to generate a series of chiral gamma-amino alcohol compounds which are important precursors for synthesizing drugs. Therefore, the halohydrin dehalogenase mutants have important application value in the industry.

Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and / or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and / or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic / methacrylic / ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

Disclosed herein are novel methods for preparing 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile, including various solvate forms and intermediates thereof. Also disclosed herein are novel solvate forms and intermediates of 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile.

The invention discloses a polyurethane adhesive with a fluorine-containing side chain and a preparation method thereof, and relates to a polyurethane adhesive and a preparation method thereof. The invention aims to solve the problem that energy loss is caused by reduction of AP high-energy components due to the fact that common fluorine-containing polymers such as PVDF and PTFE are usually added in the form of an oxidizing agent due to limitation of inherent characteristics of the fluorine-containing polymers. The preparation method comprises the following steps: step 1, purging a reaction container for 30 minutes by using high-purity nitrogen, adding an initiator and a solvent, adding a catalyst A, and mixing and reacting for 10-60 minutes; step 2, dropwise adding a fluorine-containing oxetane monomer into the reaction liquid; step 3, adding branched-chain fluorine-containing hydroxyl-terminated polyether PFOH, diisocyanate and triisocyanate into the container, stirring for 5-30 minutes, adding a catalyst B, uniformly stirring, pouring into a silica gel mold, and putting into a vacuum oven at room temperature to remove bubbles; and step 4, putting the mold into a heating oven. The invention belongs to the technical field of polyurethane synthesis.

The invention provides a preparation method of (S)-oxetane-2-methylamine. The preparation method of (S)-oxetane-2-methylamine comprises the following steps: (1) carrying out ring closing reaction on a compound A under an alkaline condition to obtain a compound B; (2) reacting the compound B with dibenzylamine to obtain a compound C; (3) reacting the compound C with a reducing agent to obtain a compound D; (4) reacting the compound D with paratoluensulfonyl chloride to obtain a compound E; (5) reacting the compound E with alkali to obtain a compound F; and (6) carrying out a reaction on the compound F and palladium on carbon to obtain the (S)-oxetane-2-methylamine. According to the preparation method provided by the invention, ring expansion reaction using trimethylsulfoxide iodide in the prior art is avoided, the problem that residual sulfur elements cause poisoning of a palladium-carbon catalyst is solved, meanwhile, sodium azide is also avoided, and the preparation method is safe and reliable in process, high in chiral purity and yield and suitable for industrial large-scale production.

Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising at least one compound chosen from PRN1008 and pharmaceutically acceptable salts thereof are also disclosed.

The present application relates to a kind of bismaleimide resin compositions and the semi-cured sheet and laminated plate prepared therefrom, comprising components: bismaleimide compound, allyl phenol compound and oxetane compound, the equivalent ratio range of double bond in the bismaleimide compound and double bond in the allyl phenol compound is 3~0.3, the oxetane compound accounts for 0.5~5% of the overall resin, the preparation process of semi-cured sheet and laminated plate includes the following preparation steps: step S1, the glue liquid prepared by bismaleimide resin composition is infiltrated into glass fiber cloth, and then baked and dried to obtain semi-cured sheet;Step S2, the surface of semi-cured sheet is covered with metal foil, and high-temperature pressing is formed, the advantage of the present application is that the glue liquid of resin composition, semi-cured sheet has good storage property, and the laminated plate prepared therefrom has excellent heat resistance, copper foil bonding force and moisture resistance.

Disclosed herein are novel formulations of 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile, including formulations including various solid forms thereof. Also disclosed are processes for preparing formulations of 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetan-3-yl)piperazin-1-yl]-pent-2-enenitrile.

The present invention addresses the problem of providing: a resin composition that is capable of at least being photocured or being cured at low temperature (for example, 100°C or less) and that provides a cured product that exhibits excellent adhesive strength and high heat-resistance reliability; an adhesive agent or a sealing material that includes the same; a cured product thereof; and a semiconductor device and an electronic component that include the cured product.　Provided are: a resin composition containing (A) an epoxy compound, (B) an oxetane compound, and (C) an acid-generating agent that is a salt of an anion represented by formula (1) (In the formula, R1, R2, R3, and R4 independently represent an alkyl group having 1-18 carbon atoms or an aryl group having 6-14 carbon atoms, provided, however, that at least one of R1, R2, R3, and R4 represents an aryl group having 6-14 carbon atoms.) and of a counter cation, and also satisfying at least one of the following characteristics (a) and (b); an adhesive agent or a sealing material including the same; a cured product thereof; and a semiconductor device and an electronic component including the cured product. (a) (D) A filler is further included. (b) The content of (A) the epoxy compound is 100-1300 parts by weight with respect to 100 pats by weight of (B) the oxetane compound.

Disclosed is a method for preparing oxetan-2-ylmethanamine, which belongs to the field of organic synthesis. [2-(1-ethoxyethoxy)methyl]propylene oxide is used as an initial raw material, and reacted in the presence of potassium tert-butoxide and trimethylsulfoxonium iodide; the resulting product is reacted with a sulfonyl compound and triethylamine; the resulting product is reacted with a compound of phthalimide; the resulting product is reacted with an amino group-containing compound, to obtain oxetan-2-ylmethanamine. The method according to the disclosure allows for an overall yield of not less than 30% in scale-up production (kilogram level), which is higher. Moreover, compared with the traditional method for preparing oxetan-2-ylmethanamine, a palladium-carbon catalytic hydrogenation step is not required, and dangerous chemical-sodium azide is not required in the method according to the disclosure. Thus, the method has high safety, low production cost, simple operations, and thereby is suitable for industrial production.

The present invention relates to oxetane-based compounds, a method of manufacturing oxetane-based compounds, and to applications of the same.

A resin composition includes a coloring material, a resin, and a solvent. The resin includes a graft polymer which has a main chain including a molecular chain having a structure derived from a compound having an ethylenically unsaturated bond-containing group and a graft chain, and the graft chain includes a repeating unit p1 having an oxetane group. The resin composition may be employed in a film formed of the resin composition; an optical filter; a solid-state imaging element; and an image display device.

Disclosed herein is a method of treating pemphigus in a human patient in need thereof, comprising administering to the human patient a dose of at least 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) once daily (QD) or twice daily (BID).

The present invention relates to a method for preparing a hydroxyl- or epoxy-group-containing organic phosphate from an epoxy compound, comprising the following steps: mixing a P(O)-OH compound and an epoxy compound under air, stirring for reaction, cooling, and purifying to obtain a hydroxyl- or epoxy-group-containing organic phosphate as shown in Formula I, wherein the epoxy compound is one of epichlorohydrin, methylepichlorohydrin, oxetane, and cyclohexene oxide, and the epoxy compound serves as both a reaction substrate and a reaction solvent; R 1 、R 2 are selected from one or two of aryl, substituted aryl, aliphatic, ether, hydroxyl and hydrogen atoms; R 3 The present invention provides a method for preparing an organophosphate compound directly from a P(O)-OH compound and an epoxy compound under solvent-free and additive-free conditions. The raw materials are inexpensive, readily available, green and stable, with high atom economy. The reaction conditions are simple and mild, and the reaction can be carried out efficiently without any additives.

The present invention refers to a light emitting diode (LED) curable composition, wherein the composition comprises a cationic curable resin comprising a1) an epoxide, a2) an oxetane, a3) a cationic initiator, and a4) a photosensitizer, wherein the weight ratio between the epoxide a1) and the oxetane a2) is in the range of 1-5. The present invention also refers to the use of said LED curable composition for producing a coating that is cured with a LED light source at a wavelength in the range of 275-405 nm.

The application discloses a kind of for tape bottom layer on ultraviolet light solidification dip coating ink, the ultraviolet light solidification dip coating ink is composed of the following weight parts of component: photocuring oligomer: 30-50 parts, functional active monomer: 20-50 parts, photo initiator: 3-6 parts pigment: 5-35 parts, dispersing agent: 1-3 parts, surface auxiliary agent: 1-2 parts;The synthesis steps of the photocuring oligomer are: after epoxy E51 is mixed with octandioic acid, under the condition of nitrogen protection, temperature is controlled 115 DEG C, reaction 3-4h, when acid value is less than 10mgKOH / g, reduce reaction temperature to 85-95 DEG C, add polymerization inhibitor, slowly drop catalyst and glutaric acid-3-ethyl-3-oxetane monomethyl ester, drop adding time is controlled at 30-40min, and reaction 7-8h, when acid value is less than 10mgKOH / g, control reaction temperature to 65-75 DEG C, add isocyanatoethyl acrylate and reaction 5-6h, obtain photocuring oligomer with oxetane and acrylate structure simultaneously.The application has the characteristics of low viscosity, good leveling performance, has very good adhesion on steel tape, and solidification speed is relatively fast.

The invention provides a modified polyamide resin and a preparation method thereof, the modified polyamide resin comprises a structural unit derived from binary acid and diamine, and an end-capping structure derived from an oxetane compound of formula (I): (I) wherein R1 is C1-C6 alkyl, R2 is C1-C12 hydroxyalkyl or C2-C6 alkyl interrupted by an ether bond; wherein the molar ratio of the diamine to the binary acid is 1: (1-1.01); the mass of the oxetane compound is 1-3% of the mass of the modified polyamide resin; the number-average molecular weight of the modified polyamide resin is 25000 to 35000.

The utility model discloses a wear-resistant automobile cover which comprises an automobile cover body, the automobile cover body comprises a self-repairing layer, an ultraviolet-proof layer, a waterproof layer, a heat dissipation layer and a bottom cover, and the self-repairing layer, the ultraviolet-proof layer, the waterproof layer, the heat dissipation layer and the bottom cover are sequentially arranged from top to bottom. The self-repairing layer is a polyurethane coating containing chitosan and an oxetane structure, the bottom cover is made of polyester fibers, and by arranging the self-repairing layer, when the surface of the coating is scratched, the annular structure of oxetane in the self-repairing layer is broken and can generate chemical reaction after being exposed, and when ultraviolet light irradiates, the surface of the coating is not damaged, so that the surface of the coating is not damaged. The exposed tail ends of the chitosan and the oxetane in the coating attract each other and are combined together to repair the annular structure, so that the self-repair of the damaged part of the coating is realized, and the wear resistance and the practicability of the automobile cover are improved.

This invention discloses a microRNA-responsive 1,2-dioxane-based chemiluminescent compound, its dual-probe system, kit, synthesis method, and applications. The compound's core is an o-acrylate-substituted phenoxyadamantane-1,2-dioxane, with the phenolic hydroxyl group protected by an azide benzyl group. The two-component probe system constructed based on this compound comprises an azide-modified first probe and a phosphine-modified second probe, each complementary to different segments of the target microRNA. Hybridization brings the two probes closer, triggering a Staudinger reaction to remove the protecting group and activate the chemiluminescent signal. This probe system requires no enzyme amplification or nucleic acid extraction, achieves a detection limit of 1.37 fM, and a signal-to-noise ratio as high as 157-fold. It can be successfully used for real-time imaging of endogenous microRNA-21 in live cells, showing broad application prospects in early tumor screening, auxiliary diagnosis, and prognostic assessment.

The present invention relates to the technical field of carbon nanotube modification, specifically a flame-retardant carbon nanotube conductive material and a preparation process thereof. The method comprises the following steps: S1: reacting chlorinated carbon nanotubes with 4-aminobenzophenone and DOPO in sequence to obtain DOPO-carbon nanotubes; S2: reacting chain polyphosphazenes with (1-hydroxyallyl)trimethylsilane and oxetane-3-thiol in sequence to obtain oxacyclic-chain polyphosphazenes; and S3: mixing DOPO-carbon nanotubes, oxacyclic-chain polyphosphazenes, and pyrrole to prepare the flame-retardant carbon nanotube conductive material.

Provided are a curable composition, a curable ink composition, and a curable ink composition for inkjet, each of which has low viscosity, low volatility, and curability. And methods of using these compositions are provided. The curable composition contains an epoxy / oxetane compound represented by chemical formula (I). In the formula, n is the same or different and represents an integer of 2-5.

Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and / or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and / or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic / methacrylic / ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.

A novel crystalline form of a GLP-1 receptor agonist, its preparation method, its pharmaceutical composition, and its use are provided. The GLP-1 receptor agonist is designated Compound I, i.e., (S)-2-((4-(6-((2-fluoro-4-(oxetan-3-yl)benzyl)oxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid.

The present invention relates to compounds of formula (I) as activators of glucagon-like peptide 1 (GLP1) receptor for the treatment of obesity, type 2 diabetes, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, one or more diabetic complications, diabetic nephropathy, dyslipidemia, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), hypertension, atherosclerosis, peripheral arterial disease, stroke, cardiomyopathy, atrial fibrillation, heart failure, coronary heart disease, and neuropathy.Preferred compounds are, for example, 2-((4-((S)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-imidazole derivatives and similar compounds, such as C-1, C-2, C-3, C-4 and other compounds. [Formula 1] TIFF2024514826000258.tif26170 [chemical 2] TIFF2024514826000259.tif58170

A photosensitive resin composition film, containing (A) a resin, (B) an epoxy compound and / or an oxetane compound, and (C) a photo-cationic polymerization initiator, wherein a transmittance Tα (%) per unit film thickness at a wavelength of 405 nm on one surface thereof and a transmittance Tβ (%) per unit film thickness at a wavelength of 405 nm on the other surface thereof satisfy formula (1), which is Tα > Tβ, and with respect to the thickness of the photosensitive resin composition film, a content C10 (mass%) of the photo-cationic polymerization initiator (C) at a depth of 10% from the surface on the side where the transmittance per unit film thickness at a wavelength of 405 nm is Tα (%) and a content C90 (mass%) of the photo-cationic polymerization initiator (C) at a depth of 90% from said surface satisfy formula (2) below. Provided is a photosensitive resin composition film capable of forming a high aspect ratio pattern. (2): 0.050 ≤ C10 / C90 ≤ 0.85